What one share of Heron Therapeutics, Inc. /De/ holds
We are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.
Heron Therapeutics, Inc. /De/’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.93 |
|---|---|
| Profit | −$0.21 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.07 |
| Cash and investments | $0.11 |
| Debt | $0.18 |
| Book value | $0.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | — | −$6.20 | $0.00 | −$6.80 | — | $4.20 |
| 2010 | — | −$3.80 | $0.04 | −$2.88 | — | $0.66 |
| 2011 | — | −$1.96 | $0.09 | −$1.37 | — | $1.57 |
| 2012 | — | −$1.91 | $0.08 | −$1.47 | — | $3.43 |
| 2013 | — | −$3.42 | $0.10 | −$2.63 | — | $2.92 |
| 2014 | — | −$2.87 | $0.05 | −$2.32 | — | $2.16 |
| 2015 | — | −$2.95 | $0.03 | −$2.41 | — | $3.27 |
| 2016 | $0.03 | −$4.57 | $0.08 | −$3.62 | — | −$0.54 |
| 2017 | $0.57 | −$3.65 | $0.05 | −$3.20 | — | $2.03 |
| 2018 | $1.06 | −$2.44 | $0.13 | −$2.75 | — | $4.74 |
| 2019 | $1.78 | −$2.50 | $0.09 | −$1.61 | — | $4.47 |
| 2020 | $0.98 | −$2.50 | $0.08 | −$2.11 | — | $2.59 |
| 2021 | $0.88 | −$2.24 | $0.03 | −$2.10 | — | $0.76 |
| 2022 | $0.99 | −$1.67 | $0.02 | −$1.37 | — | $0.11 |
| 2023 | $0.92 | −$0.80 | $0.01 | −$0.44 | — | −$0.23 |
| 2024 | $0.95 | −$0.09 | $0.01 | −$0.16 | — | −$0.22 |
| 2025 | $0.93 | −$0.12 | $0.00 | −$0.17 | — | $0.07 |
Common questions about Heron Therapeutics, Inc. /De/
How much does one share of Heron Therapeutics, Inc. /De/ earn?
Over the last 12 months, Heron Therapeutics, Inc. /De/ lost $0.21 for each share on $0.93 of sales.
Does Heron Therapeutics, Inc. /De/ pay a dividend?
Heron Therapeutics, Inc. /De/ didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Heron Therapeutics, Inc. /De/’s book value per share?
Heron Therapeutics, Inc. /De/’s book value is $0.03 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Heron Therapeutics, Inc. /De/ have?
Each share of Heron Therapeutics, Inc. /De/ has $0.11 of cash and investments and $0.18 of debt, as of June 30, 2026.
What is Heron Therapeutics, Inc. /De/’s free cash flow per share?
−$0.07 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Heron Therapeutics, Inc. /De/ bought back shares?
Heron Therapeutics, Inc. /De/’s share count rose about 10207% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.